Genesis Bioventures Announces Breast Cancer Marker Receives Additional US Patent Protection
LOS ANGELES--(BUSINESS WIRE)--Genesis Bioventures, Inc. (NASD OTC: GBIW) , a development stage company, announced today that Mammastatin, the breast cancer marker exclusively licensed to Genesis Bioventures, has been allowed additional patent protection by the United States Patent and Trademark Office.